Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-04-08Clinical Trial Update: A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod [Phase 2]
Phase 2 trial evaluating the effectiveness, tolerability and safety of laquinimod for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2011-04-08Clinical Trial Update: Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
A clinical trial update reports on how titration, analgesics, and BET A nurse support influence acceptance rates for Betaseron treatment in …
-
CLINICAL_TRIALS trial_result · 2011-03-16Clinical Trial Update: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of fingolimod (Gilenya) in relapsing-remitting multiple sclerosis, with results from the c…
-
CLINICAL_TRIALS research · 2010-12-06Clinical Trial Update: A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating BMS-188667 in relapsing-remitting multiple sclerosis. The study status is terminated.
-
CLINICAL_TRIALS research · 2010-12-01Clinical Trial Update: Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
An update on neurocognitive changes observed in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-10-18Clinical Trial Update: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS [Phase 4]
A Phase 4 randomized trial comparing two FDA-approved therapies for relapsing-remitting multiple sclerosis to assess disease progression was…
-
CLINICAL_TRIALS trial_result · 2010-10-15Clinical Trial Update: Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial update evaluating simvastatin as an add-on to interferon-beta-1a for relapsing-remitting multiple sclerosis. The study has com…
-
CLINICAL_TRIALS research · 2010-09-09Clinical Trial Update: A Study for Patients With Relapsing Remitting Multiple Sclerosis [Phase 2, Phase 3]
A completed Phase 2/Phase 3 clinical trial for Relapsing Remitting Multiple Sclerosis sponsored by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2010-08-27Clinical Trial Update: Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis [Phase 4]
Phase 4 study evaluating the immunogenicity and safety of recombinant human interferon beta-1a (Rebif) using Clone 484-39 in adults with rel…
-
CLINICAL_TRIALS trial_result · 2010-07-30Clinical Trial Update: Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo [Phase 3]
Phase 3 clinical trial evaluating simvastatin in relapsing-remitting multiple sclerosis patients treated with Avonex vs placebo has complete…
-
CLINICAL_TRIALS trial_result · 2010-07-05Clinical Trial Update: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 study evaluating a new formulation of Rebif (interferon-beta-1a) for relapsing-remitting multiple sclerosis has completed with resul…
-
CLINICAL_TRIALS trial_result · 2010-05-14Clinical Trial Update: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). [Phase 3]
This clinical trial update reports results from a Phase 3 study comparing two dosing regimens of glatiramer acetate for relapsing-remitting …
-
CLINICAL_TRIALS trial_result · 2010-04-29Clinical Trial Update: A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
This completed clinical trial evaluated the long-term safety and effectiveness of sequential mitoxantrone (Novantrone) therapy followed by g…
-
CLINICAL_TRIALS trial_result · 2010-03-04Clinical Trial Update: RNF and Betaseron® Tolerability Study [Phase 3]
A Phase 3 tolerability study evaluating RNF and Betaseron in relapsing-remitting multiple sclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2010-02-10Clinical Trial Update: Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) [Phase 4]
Phase 4 clinical trial evaluating glatiramer acetate in clinically isolated syndrome or early relapsing-remitting multiple sclerosis; uses o…
-
CLINICAL_TRIALS trial_result · 2010-01-26Clinical Trial Update: Natalizumab Re-Initiation of Dosing [Phase 3]
Completed Phase 3 study evaluating re-initiation of Natalizumab dosing in relapsing-remitting multiple sclerosis; results have been posted.
-
CLINICAL_TRIALS trial_result · 2010-01-14Clinical Trial Update: A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose [Phase 2]
A Phase 2 trial evaluating the safety and effectiveness of a 40 mg dose of Copaxone (glatiramer acetate) compared with the approved 20 mg do…
-
CLINICAL_TRIALS trial_result · 2009-11-09Clinical Trial Update: BEYOND Pilot Study [Phase 2]
The BEYOND Pilot Study, a Phase 2 trial sponsored by Bayer, has completed in relapsing-remitting multiple sclerosis.
-
FDA approval · 2009-10-26FDA Approved: KESIMPTA — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved Kesimpta (ofatumumab) under an original Biologics License Application from Novartis for the treatment of relapsing forms of…
-
CLINICAL_TRIALS trial_result · 2009-07-03Clinical Trial Update: Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis [Phase 2]
A Phase 2 extension study evaluates two doses of Betaseron (interferon beta-1b) for safety and tolerability in relapsing-remitting multiple …
-
CLINICAL_TRIALS trial_result · 2009-06-18Clinical Trial Update: Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating natalizumab in combination with glatiramer acetate in relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2009-06-16Clinical Trial Update: GER-009-06-AVX Early Therapy in Multiple Sclerosis
Biogen-sponsored trial evaluating early therapy with GER-009-06-AVX in Relapsing-Remitting Multiple Sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2009-06-10Clinical Trial Update: The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
A Phase 2 clinical trial evaluating the potential neuroprotective effects of lamotrigine and interferon beta-1a in patients with relapsing-r…
-
CLINICAL_TRIALS research · 2009-06-05Clinical Trial Update: Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
A trial is comparing cognitive effects of Campath (alemtuzumab) versus Rebif (interferon beta-1a) in relapsing-remitting multiple sclerosis.…
-
CLINICAL_TRIALS trial_result · 2009-03-11Clinical Trial Update: Differential Immune Effects of Natalizumab
This completed trial update reports differential immune effects observed with Natalizumab in relapsing-remitting multiple sclerosis.